Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

Globus Medical (NYSE:GMED – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday. Several other equities analysts ...

Stifel重申买入评级和94.00美元的目标价，反映了对Globus Medical并购后指引和预期财务表现的审慎评估。该分析为投资者提供了一个框架，用于衡量这家医疗器械公司在未来几年实现每股收益增长目标所需的努力。凭借2.54的健康流动比率和适度的债务水平，GMED似乎已做好执行并购战略的准备。

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Corp (NVRO – Research Report), Globus ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

HighTower Advisors LLC raised its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 2.4% during the fourth quarter, ...

Looking ahead to 2025, we expect our base GMED business SG&A expense to be in the range of 37.5% to 38.5%. The GAAP tax rate for the fourth quarter was negative 7.4% compared to 39.8% in the prior ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

Wall Street analysts expect Globus Medical (GMED) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year increase of 26.7%. Revenues are expected to ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

In trading on Tuesday, shares of Globus Medical Inc (Symbol: GMED) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $78.6301 per share. By comparison ...